Press Releases

Savings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes SAN FRANCISCO --(BUSINESS WIRE)--Nov. 28, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat

Better Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way in the North American diabetes digital behavioral therapeutics industry SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2023-- Better Therapeutics, Inc .

Company obtained FDA authorization for AspyreRx TM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--Nov. 9, 2023-- Better Therapeutics, Inc .

SAN FRANCISCO --(BUSINESS WIRE)--Nov. 8, 2023-- Better Therapeutics, Inc . (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the market opens on Thursday,

Company to showcase AspyreRx™ Company to host sponsored education session on Tuesday, October 31, 2023 ; A novel approach to treating type 2 diabetes SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics

AspyreRx is the first FDA-authorized digital behavioral therapeutic device delivering cognitive behavioral therapy for the treatment of a cardiometabolic disease As previously reported, adding AspyreRx to standard of care resulted in significant and durable reductions in A1c as well as improvements

Pivotal trial established use of AspyreRx alongside standard of care demonstrating clinically meaningful and statistically significant reduction in HbA1c leading to FDA authorization In a subgroup analysis, the use of AspyreRx and GLP-1 receptor agonists showed substantially greater A1c reductions

Authors conclude the totality of positive efficacy, safety and usability data indicates the potential of Better Therapeutics’ digitally delivered Cognitive Behavioral Therapy to help address the significant unmet clinical needs observed in MASLD and MASH Company expects to submit request to the FDA

1,000 participants enrolled across two studies, and six sites Studies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilization SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2023-- Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing

Obtained FDA Authorization for AspyreRx TM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in net proceeds Company to host conference call and webcast today at 4:30pm ET SAN